Cell and Gene Therapy CDMO Market Research Report By Product (Cell Therapy, Gene Therapy), By Service (Contract Development, Contract Manufacturing), By Application (Oncology, Immunology, Neurology, Cardiovascular, Other Diseases), By End User (Biopharmaceutical Companies, Academic Institutions, Hospitals, Other End Users) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Cell and Gene Therapy CDMO Market Overview

As per MRFR analysis, the Cell and Gene Therapy CDMO Market Size was estimated at 19.04 (USD Billion) in 2022. The Cell and Gene Therapy CDMO Market Industry is expected to grow from 23.52(USD Billion) in 2023 to 157.5 (USD Billion) by 2032. The Cell and Gene Therapy CDMO Market CAGR (growth rate) is expected to be around 23.53% during the forecast period (2024 - 2032).

Key Cell and Gene Therapy CDMO Market Trends Highlighted

Innovative approaches in cell and gene therapies are driving the growth of the contract development and manufacturing organization (CDMO) market. The increasing complexity and regulatory requirements associated with these therapies necessitate specialized expertise and infrastructure, leading to the outsourcing of manufacturing processes to CDMOs.Technological advancements, such as gene editing techniques and stem cell engineering, are creating new opportunities for cell and gene therapies. CDMOs are investing in these technologies to expand their service offerings and cater to the growing demand. The rise of personalized medicine and targeted therapies further drives the market, as CDMOs provide customized manufacturing solutions tailored to specific patient needs.Recent trends in the CDMO market include the increasing adoption of artificial intelligence (AI) and automation to streamline manufacturing processes and enhance efficiency. The integration of digital technologies, such as cloud computing and data analytics, allows for real-time monitoring and optimization of manufacturing operations. Additionally, strategic partnerships between CDMOs and academic institutions are fostering innovation and accelerating the development of novel therapies.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Cell and Gene Therapy CDMO Market Drivers

Advancements in Cell and Gene Therapies

The area of cell and gene therapy is constantly developing, and new technologies are being discovered. They allow for more effective and reputably targeted treatment of various diseases. As a result, the demand for CDMOs that specialize in cell and gene therapy will increase dramatically. Contract development and manufacturing organizations are significantly involved in the creation and production of these therapies, and growth in this area can increase demand for many services provided by CDMOs even more.The most widely used services are process development, analytical testing, clinical trial manufacturing, and commercial-scale manufacturing. With these already available, cell and gene companies have better resources for product implementation. There are numerous factors contributing to the development of cell and gene therapy and growth of demand for its products. One of the first factors is the prevalence of chronic diseases. The global population is becoming older, and more people are expected to suffer from diseases like cancer and autoimmune disorders.Additionally, the lifestyle of people also deteriorates, which leads to chronic diseases. Another significant growth factor is the growing population of the world. Finally, the increased awareness of the population about cell and gene therapies resulted in higher demand for these types of treatment. Moreover, the recent success of clinical trials and popular people using the therapies increased the demand significantly. Finally, many governments support cell and gene therapy for the benefit of patients and healthcare providers, as new therapies can be both effective and cheaper.

Rising Prevalence of Chronic Diseases

The rise in the prevalence of chronic diseases is one of the significant factors that are boosting the growth of the Global Cell And Gene Therapy Contract Development And Manufacturing Organism Market Industry. Chronic diseases such as cancer, heart disease, and diabetes are becoming increasingly prevalent across the globe. This is because of several reasons, such as the increasing aging population, the adoption of unhealthy lifestyles, and the increasing prevalence of toxins.This has created a substantial unmet medical need. This is because most of these diseases are untreatable using other techniques. Many people, however, demand new treatment following the advancement of cell and gene therapies.

Technological Advancements

One of the main reasons for the development of the Cell and Gene Therapy CDMO Market Industry is the pace of technological development. In the past few years, much has changed in our understanding of cell and gene biology. Furthermore, numerous advances promote the development of innovative cell and gene therapies. For instance, research has helped devise new ways to modify cells genetically, which is important as it has been found that such an approach will help produce more effective treatments that are also less likely to damage the biological structure of a subject.Moreover, the same advancement can minimize the cost of such therapy.

Cell and Gene Therapy CDMO Market Segment Insights

Cell and Gene Therapy CDMO Market Product Insights

The Cell and Gene Therapy CDMO Market is segmented by product into cell therapy and gene therapy. The cell therapy segment is expected to hold a larger share of the market in 2023 and is projected to continue to grow at a faster rate through 2032. This growth is attributed to the increasing prevalence of chronic diseases, such as cancer, and the growing adoption of cell-based therapies for the treatment of these diseases. The gene therapy segment is also expected to experience significant growth over the forecast period.This growth is driven by the increasing number of gene therapy clinical trials and the growing number of gene therapy products that are being approved for commercial use. In 2023, the Cell and Gene Therapy CDMO Market for cell therapy is estimated to be valued at 12.5 billion USD. This segment is expected to grow at a CAGR of 25.3% over the forecast period, reaching a value of 78.6 billion USD by 2032. The Cell and Gene Therapy CDMO Market for Gene Therapy is estimated to be valued at 11.02 billion USD in 2023.This segment is expected to grow at a CAGR of 22.2% over the forecast period, reaching a value of 66.9 billion USD by 2032. The growth of the Cell and Gene Therapy CDMO Market is being driven by a number of factors, including the increasing prevalence of chronic diseases, the growing adoption of cell-based and gene-based therapies, and the increasing number of gene therapy clinical trials.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Cell and Gene Therapy CDMO Market Service Insights

The Service segment in the Cell and Gene Therapy CDMO Market is expected to dominate over the forecast period. Contract development services consist of various services such as cell line development, process development and analytical development. Contract manufacturing service is into the bulk production of cell and gene therapies with the adherence to good manufacturing practice standards. The demand for cell and gene therapy has increased which is used to treat cancer and other rare diseases. This has increased the demand for the services offered to develop and manufacture cell and gene therapy.Thus, the Service accounted for a considerable share of revenue of the Cell and Gene Therapy CDMO Market and is assessed to be around 10.24 billion USD as of 2023.

Cell and Gene Therapy CDMO Market Application Insights

Application Segment Insight and Overview The Cell and Gene Therapy CDMO Market is segmented into several applications, including Oncology, Immunology, Neurology, Cardiovascular, and Other Diseases. The Oncology segment holds the largest market share due to the high prevalence of cancer and the increasing demand for personalized cancer therapies. The Immunology segment is expected to grow rapidly in the coming years due to the rising incidence of autoimmune diseases and the development of novel immunotherapies.The Neurology segment is also poised for significant growth due to the increasing prevalence of neurological disorders and the development of new gene therapies for these conditions. The Cardiovascular segment is expected to witness steady growth due to the rising incidence of cardiovascular diseases and the increasing demand for cell-based therapies to treat these conditions. The Other Diseases segment includes various applications, such as ophthalmology, dermatology, and metabolic disorders, and is expected to contribute to the overall growth of the market.

Cell and Gene Therapy CDMO Market End User Insights

The Cell and Gene Therapy CDMO Market is segmented by end user into Biopharmaceutical Companies, Academic Institutions, Hospitals, and Other End Users. Among these, Biopharmaceutical Companies held the largest market share in 2023, accounting for over 50% of the Cell and Gene Therapy CDMO Market revenue. This dominance can be attributed to the increasing demand for outsourced cell and gene therapy development and manufacturing services by biopharmaceutical companies, which lack the necessary infrastructure and expertise to conduct these complex processes in-house.Academic Institutions are expected to witness the fastest growth during the forecast period, owing to the rising number of research collaborations between academia and industry players.

Cell and Gene Therapy CDMO Market Regional Insights

The Cell and Gene Therapy CDMO Market is segmented into five major regions, including North America, Europe, APAC, South America, and MEA. Among these regions, North America held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period owing to the presence of a large number of Contract Development And Manufacturing Organizations (CDMOs) and a supportive regulatory landscape. Europe is another significant market for Cell and Gene Therapy CDMO Market, driven by factors such as increasing government funding for cell and gene therapy research and the presence of leading pharmaceutical companies.The APAC region is expected to witness the highest growth rate during the forecast period due to rising healthcare expenditure and growing awareness about cell and gene therapies. South America and MEA represent emerging markets for Cell and Gene Therapy CDMO Market, with increasing investment in healthcare infrastructure and growing demand for cell and gene therapies.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Cell and Gene Therapy CDMO Market Key Players And Competitive Insights

Most of the major providers operating in the Cell and Gene Therapy CDMO market are investing in research and development to expand the scope of their services and gain an edge over their competitors. In addition, expansion is another strategy used by prominent players in the Cell and Gene Therapy CDMO market to accommodate the region-wise growth in demand across various industry sectors. The Cell and Gene Therapy CDMO market is anticipated to remain a highly fragmented marketplace and see the presence of a multitude of small and medium-sized players and a few large players within the market.

The leading market players in the Cell and Gene Therapy CDMO market are focusing on the development of novel technologies and expanding their presence in new geographies. One of the biggest players in the Cell and Gene Therapy CDMO market is Catalent, Inc. Catalent offers a comprehensive range of services such as cell and gene therapy development, delivery, manufacturing, and testing.

Founded in 2007 and headquartered in Somerset, the United States, Catalent has a huge customer base and is swiftly expanding in Asia and Europe. A team of more than 1,300 scientists is continually contributing to the cell and gene therapy sector. One of the notable companies offering services relatively similar to that of Catalent, Inc. is Lonza. The key characteristic is that Lonza and the client are located in North America, Europe, and Asia. The expert scientific team is also interested in investing more in research and development.

Key Companies in the Cell and Gene Therapy CDMO Market Include

• Fujifilm Diosynth Biotechnologies


• Charles River Laboratories


• WuXi AppTec


• Thermo Fisher Scientific


• Catalent


• AGC Biologics


• Lonza


• Samsung Biologics


• Evotec


• Cobra Biologics

Cell and Gene Therapy CDMO Market Industry Developments

The Cell and Gene Therapy CDMO (CDMO) market is projected to grow significantly over the next decade, driven by the increasing demand for cell and gene therapies. The market is expected to reach a value of USD 157.5 billion by 2032, with a CAGR of 23.53% from 2024 to 2032.

Key market players include Lonza, Thermo Fisher Scientific, and Catalent. Recent developments in the market include the acquisition of Brammer Bio by Thermo Fisher Scientific and the expansion of Catalent's cell and gene therapy manufacturing capacity.

Cell and Gene Therapy CDMO Market Segmentation Insights

• Cell and Gene Therapy CDMOMarket Product Outlook


• Cell Therapy


• Gene Therapy

• Cell and Gene Therapy CDMOMarket Service Outlook


• Contract Development


• Contract Manufacturing

• Cell and Gene Therapy CDMOMarket Application Outlook


• Oncology


• Immunology


• Neurology


• Cardiovascular


• Other Diseases

• Cell and Gene Therapy CDMOMarket End User Outlook


• Biopharmaceutical Companies


• Academic Institutions


• Hospitals


• Other End Users

• Cell and Gene Therapy CDMOMarket Regional Outlook


• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa